Search the Newsreel

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of "Moderate Buy" by Analysts

Stoke Therapeutics (NASDAQ:STOK) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $43.00, despite recently missing earnings per share estimates while exceeding revenue forecasts. Insider sales by two executives under pre-arranged plans have been noted, though insiders …

Oneok Inc. (OKE) Q2 Earnings and Revenues Beat Estimates

Oneok Inc. (OKE) reported strong Q2 earnings of $1.53 per share, surpassing the Zacks Consensus Estimate of $1.39 and showing a significant increase from $1.34 a year ago. The company also exceeded revenue expectations, posting $12.05 billion against an estimated $10.66 billion. While Oneok's …

Interactive Brokers Group Reports Brokerage Metrics and Other Financial Information for July 2026, includes Reg.-NMS Execution Statistics

GREENWICH, Conn., August 03, 2026--(BUSINESS WIRE)--Interactive Brokers Group, Inc. (Nasdaq: IBKR) an automated global electronic broker, today reported its Electronic Brokerage monthly performance metrics for July. Brokerage highlights for the month included: 4.426 million Daily Average Revenue Trades (DARTs)1, 27% higher than prior year …

Why Houlihan Lokey (HLI) Could Be a Stock to Watch in a Volatile Market

Ariel Investments, an investment management company, released its "Appreciation Fund" Q2 2026 investor letter. A copy of the letter can be downloaded here. The fund gained 13.71% in the second quarter of 2026, slightly outperforming the Russell Midcap Value Index's 13.40% return but trailing …

ONEOK boosts 2026 forecast as higher NGL volumes boost quarterly profit

ONEOK has revised its 2026 forecast upwards, attributing this positive adjustment to increased natural gas liquids (NGL) volumes. This improvement in NGL volumes also contributed to a boost in the company's quarterly profit. The article also notes recent analyst rating changes and price target …

Stoke Therapeutics (NASDAQ:STOK) Issues Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Stoke Therapeutics reported a quarterly loss of $0.93 per share, missing analyst estimates by $0.13, despite revenue of $9.32 million exceeding expectations. The company remains unprofitable, but its shares rose by $0.70 to $29.56 following the announcement. Analysts maintain a "Moderate Buy" consensus with …

Compared to Estimates, Oneok (OKE) Q2 Earnings: A Look at Key Metrics

Oneok Inc. (OKE) reported $12.05 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 52.8%. EPS of $1.53 for the same period compares to $1.34 a year ago. The reported revenue represents a surprise of +13.03% over the Zacks …

ONEOK (OKE) Releases Q2 2026 Earnings: Revenue and Profit Jump

ONEOK (OKE) reported stronger-than-expected Q2 2026 earnings with revenue reaching $12.0 billion and net income attributable to common shareholders increasing to $966 million. Diluted EPS was $1.53, and operating cash flow stood at $2.1 billion. The article also details significant hedge fund activity, congressional …

ONEOK Announces Higher Second-Quarter 2026 Earnings: Net Income up 13%, Adjusted EBITDA up 7%

ONEOK, Inc. reported strong second-quarter 2026 results with a 13% increase in net income to $967 million and a 7% increase in adjusted EBITDA to $2.12 billion. The company also raised its 2026 financial guidance, reflecting continued strong business performance and strategic growth projects. …

Earnings Flash (STOK) Stoke Therapeutics, Inc. Reports Q2 Revenue $9.3M, vs. FactSet Est of $4.9M

Stoke Therapeutics (NASDAQ: STOK) swings to H1 2026 loss as revenue falls

Stoke Therapeutics reported a significant financial downturn in H1 2026, swinging to a net loss of $111.6 million compared to a net income of $89.4 million in H1 2025, primarily due to a sharp decline in revenue from $172.4 million to $15.6 million. This …

Stoke's Dravet trial enrolls 162; data readout anticipated Q3 2027

Stoke Therapeutics announced the completion of enrollment for its Phase 3 EMPEROR study of zorevunersen in Dravet syndrome, with 162 patients enrolled and a data readout expected in Q3 2027. The company is preparing for a rolling U.S. NDA submission to begin in Q1 …

Earnings call transcript: Stoke Therapeutics posts Q2 2026 revenue beat as Dravet drug advances

Stoke Therapeutics reported a wider-than-expected Q2 2026 loss but significantly beat revenue forecasts, driven by the advancement of its Dravet syndrome drug, zorevunersen, towards a potential U.S. launch in early 2028. The company's Phase III EMPEROR study has exceeded enrollment targets with no patient …

ONEOK Shares Fall Ahead of Earnings as Energy Sentiment Softens

ONEOK (OKE) shares fell 3.1% ahead of its Q2 2026 earnings release, influenced by a general softening in energy sector sentiment and a recent analyst downgrade citing concerns about Bakken growth. The decline was also exacerbated by a sharp drop in oil prices due …

ONEOK Inc. stock underperforms Monday when compared to competitors

ONEOK Inc. (OKE) shares dropped 1.67% on Monday, closing at $88.24, despite a strong overall market performance where the S&P 500 and Dow Jones Industrial Average both saw significant gains. This decline leaves ONEOK Inc. 8.15% below its 52-week high. The article highlights the …

Houlihan Lokey (HLI) Leads North American M And A Volume, Is It Still 19% Undervalued?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Houlihan Lokey (NYSE:HLI) has been recognized as the leading M&A adviser by deal volume in North America for the first half of 2026. The ranking …

ONEOK earnings up next: Can Permian offset Bakken worries?

ONEOK Inc. is set to report second-quarter earnings, with analysts watching whether strong Permian Basin volumes can counteract concerns about its Bakken operations. While analysts expect increased earnings per share and revenue, some express caution due to investor doubts about sustained EBITDA growth and …

What Are Wall Street Analysts' Target Price for Interactive Brokers Stock?

Stock exchange market chart data on LED display by Golden House Images via Adobe Stock Greenwich, Connecticut-based Interactive Brokers Group, Inc. (IBKR) operates as an automated electronic broker. Valued at $149.3 billion by market cap, the company specializes in executing and clearing trades in …

Seaport Global Adjusts Price Target on ONEOK to $100 From $95, Maintain Buy Rating

Seaport Global has increased its price target for ONEOK (OKE) to $100 from $95, while reiterating a "Buy" rating on the stock. This adjustment reflects an updated outlook from the firm regarding the natural gas distributor. The article also notes other recent analyst rating …

ONEOK, Inc. $OKE Shares Sold by Edgestream Partners L.P.

Edgestream Partners L.P. significantly reduced its stake in ONEOK, Inc. by 70.9% in the first quarter, selling 54,730 shares while retaining 22,436 shares valued at $2.03 million. Despite this, institutional investors collectively hold 69.13% of ONEOK's stock. The company recently declared a quarterly dividend …

ONEOK Inc's Dividend Analysis

This article first appeared on GuruFocus. Assessing the Sustainability and Growth of ONEOK Inc's Upcoming Dividend Payment ONEOK Inc (NYSE:OKE) recently announced a total dividend of $1.07 per share, with the ex-dividend date set for 2026-08-03. This includes a $1.07 per share cash dividend …

Stoke Therapeutics faces earnings test as Dravet drug awaits data

Earnings To Watch: Okeanis Eco Tankers Corp (ECO) Q2 2026 -- GF Value Sees 44% Downside

Stoke Therapeutics earnings missed by $0.16, revenue topped estimates

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

ONEOK Number of Employees 2026 | Employee Count & Headcount Data

ONEOK, Inc. (OKE) has approximately 6,360 employees worldwide as of March 2026, marking a 5.2% growth since 2023 but a 0.2% decline year-over-year in 2026. The company, headquartered in Tulsa, Oklahoma, actively seeks new hires but has seen a significant 42.6% drop in job …

Suncoke Energy Earnings Call Signals Upbeat 2026 Outlook

SunCoke Energy reported a significant increase in Q2 2026 consolidated adjusted EBITDA, reaching $69.6 million, primarily due to the Phoenix acquisition and strong terminal volumes. The company raised its full-year EBITDA guidance to $250-$265 million and declared a $0.12 quarterly dividend. Both domestic coke …

Stoke Therapeutics, Inc. $STOK Shares Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC increased its stake in Stoke Therapeutics (NASDAQ:STOK) by 11.2% in the first quarter, now owning over 1.6 million shares valued at approximately $52.5 million. Despite a quarterly loss, analyst sentiment remains positive with a "Moderate Buy" consensus rating and an …

ONEOK, Inc. $OKE Position Increased by Bank of America Corp DE

Bank of America Corp DE increased its position in ONEOK, Inc. (NYSE:OKE) by 5.2% in the first quarter, now holding 5.5 million shares valued at approximately $497.6 million. Institutional investors collectively own 69.13% of ONEOK, a midstream energy company. Analyst sentiment remains mixed, with …

HOFT Q2 2026 Earnings: EPS of $0.10 Delivers 345% Surprise as Shares Slip - Earnings Preview

ONEOK, Inc. $OKE Stock Position Lowered by Kentucky Retirement Systems

Kentucky Retirement Systems significantly reduced its stake in ONEOK (OKE) by 56.6% in the first quarter, selling over 22,000 shares. Despite this, institutional investors still hold a substantial 69.13% of the company. Analysts maintain a "Hold" consensus rating with a target price of $91.81, …

GKV Capital Management Co. Inc. Purchases 34,823 Shares of ONEOK, Inc. $OKE

GKV Capital Management Co. Inc. significantly increased its stake in ONEOK, Inc. (NYSE:OKE) by 242.4% in the first quarter, acquiring an additional 34,823 shares to hold a total of 49,186 shares valued at $4.88 million. Despite the substantial investment and positive long-term EPS forecast …

Argent Capital Management LLC Lowers Holdings in Houlihan Lokey, Inc. $HLI

REAX Q1 2026 Earnings: Narrower Loss Beats Estimates, But Shares Dip 2.4% - Cash Flow Report

Wall Street Zen Downgrades Hooker Furnishings (NASDAQ:HOFT) to Buy

Wall Street Zen has downgraded Hooker Furnishings (NASDAQ:HOFT) from a "strong buy" to a "buy" rating. This comes amidst mixed ratings from other analysts, with the stock's average rating on MarketBeat being "Reduce." Despite the downgrade, Hooker Furnishings recently surpassed quarterly earnings expectations, reporting …

Alpine Woods Capital Investors LLC Has $1.72 Million Stock Position in Houlihan Lokey, Inc. $HLI